What Is Cagrilintide?
Cagrilintide is a long-acting amylin analogue under investigation for chronic weight management. Amylin is a naturally occurring hormone released by the pancreas alongside insulin after meals. Researchers are studying cagrilintide because it appears to enhance satiety, slow gastric emptying, and reduce food intake. It has also been investigated in combination with GLP-1 receptor agonists for additive effects on weight loss.
How It Works
Cagrilintide mimics the actions of amylin by activating amylin and calcitonin receptors in the brain and gastrointestinal tract. These pathways help regulate appetite, meal size, gastric emptying, and feelings of fullness. Unlike GLP-1 medications, cagrilintide targets a complementary hormone pathway, making combination therapy an area of active research.
Potential Benefits Being Studied
Current studies are evaluating cagrilintide for obesity, long-term weight management, reduction in calorie intake, improvement in metabolic health, and use alongside GLP-1 receptor agonists such as semaglutide. Clinical trials have demonstrated meaningful weight-loss potential, although research is ongoing.
Typical Research Dosing
Clinical trial dosing has varied depending on the protocol, generally involving gradual dose escalation with once-weekly subcutaneous administration to improve tolerability. There is no single investigational dosing schedule appropriate for every study.
Administration
Most research protocols utilize once-weekly subcutaneous injection. Dose escalation is commonly incorporated into study designs to reduce gastrointestinal side effects.
Possible Side Effects
The most frequently reported adverse effects include nausea, vomiting, decreased appetite, constipation, diarrhea, abdominal discomfort, and injection-site reactions. Gastrointestinal symptoms are generally most noticeable during dose escalation.
Contraindications and Precautions
As with other appetite-regulating medications, caution is warranted in individuals with significant gastrointestinal disease or other conditions identified by a healthcare professional. Long-term research continues to evaluate safety and effectiveness.
Bottom Line
Cagrilintide represents a promising addition to metabolic medicine by targeting the amylin pathway rather than the GLP-1 pathway alone. Early clinical results suggest it may further enhance weight-loss outcomes, particularly when combined with complementary therapies, but ongoing studies will better define its long-term role.
Educational Reminder
This document is provided for educational purposes only. Cagrilintide remains under active clinical investigation for several metabolic applications.